Drug Trial Radar · NCT00709410
Mass Oral Cholera Vaccination in Zanzibar
Last checked: Nov 20, 2026Latest source record: Mar 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51,151
Actual
Start
Jan 2009
Primary completion
Feb 2009
Study completion Dec 2011
Sponsor
- Lead sponsor
- International Vaccine InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health and Social Welfare, Zanzibar; National Institute of Cholera and Enteric Diseases, India; Bill and Melinda Gates Foundation; World Health Organization
- First posted
- Jul 3, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to conduct cholera vaccinations in high-risk populations in Zanzibar in order to estimate herd protection conferred by the vaccine,estimate effectiveness of the vaccine, and describe the interaction of vaccination and improved water supply on the burden of cholera and diarrhoeal diseases.
Conditions
- Cholera
- Diarrhea
Interventions
rBS-WC vaccineBiological
1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Receipt of 2 complete or nearly complete swallowed doses of oral cholera vaccineTime frame: after completion of the vaccination campaign
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ministry of Health and Social Welfare, Zanzibar
Zanzibar, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.